MYC and lip and oral cavity carcinoma: We propose to separate head and neck cancers into oral cancer and oropharyngeal cancer groups, separate them again into risk factors-associated or -non-associated groups, then use NGS to identify cancer drivers or screening of known druggable targets such as EGFR, FGFR and PIK3CA alterations, HRAS, CCND1 and MYC mutations, which have been identified in oral cancers [7], in addition to PD-L1 in these patients, to reach the initial precision medicine in oral cancer patients (Figure 4).